EAM
RVNC

Erste Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Erste Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-66,500
Closed -$1.3M – 442
2018
Q4 		$1.3M Buy
+66,500
New +$1.47M 0.09% 210

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Erste Asset Management's RVNC Position: Q1 2019 in Review

Erste Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2019, closing a stake of 66,500 shares — an estimated $1.3M sold.

Erste Asset Management first reported a position in RVNC in Q4 2018 and held it in 1 quarter. The position peaked at $1.3M in Q4 2018. 112 funds tracked by Wall St. Rank hold RVNC as of Q1 2019.

  • Erste Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Erste Asset Management sold 66,500 Revance Therapeutics, Inc. shares in Q1 2019, an estimated $1.3M.
  • Erste Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Erste Asset Management's Revance Therapeutics, Inc. position peaked at $1.3M in Q4 2018.
  • 112 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2019.

Based on Erste Asset Management's 13F filing for Q1 2019, filed 22 Nov 2024.